Cancer Journal

Papers
(The median citation count of Cancer Journal is 2. The table below lists those papers that are above that threshold based on CrossRef citation counts [max. 250 papers]. The publications cover those that have been published in the past four years, i.e., from 2020-03-01 to 2024-03-01.)
ArticleCitations
Epidemiology of Triple-Negative Breast Cancer122
Lymphoma Classification68
Immunotherapy in Triple-Negative Breast Cancer36
Menin Inhibitors in Acute Myeloid Leukemia—What Does the Future Hold?28
Molecular Classification and Treatment of Diffuse Large B-Cell Lymphoma and Primary Mediastinal B-Cell Lymphoma23
Cytokine Release Syndrome Biology and Management22
Adjuvant and Neoadjuvant Treatment of Triple-Negative Breast Cancer With Chemotherapy22
Definition, Biology, and History of Oligometastatic and Oligoprogressive Disease19
Immunotherapy in EGFR-Mutant and ALK-Positive Lung Cancer18
PARP Inhibitors in Pancreatic Cancer18
Novel Therapeutic Approaches and the Evolution of Drug Development in Advanced Kidney Cancer18
Oligometastatic and Oligoprogression Disease and Local Therapies in Prostate Cancer17
The Immunotherapy Revolution in Kidney Cancer Treatment17
Menopausal Hormone Replacement Therapy and Reduction of All-Cause Mortality and Cardiovascular Disease17
Circulating Tumor DNA Biomarkers for Early Detection of Oligometastasis15
Challenges and Errors in Genetic Testing15
HIV Lymphoma and Burkitts Lymphoma13
Triple-Negative Breast Cancer13
Radiation in the Treatment of Oligometastatic and Oligoprogressive Disease13
How We Incorporate Venetoclax in Treatment Regimens for Acute Myeloid Leukemia12
Radiomics, Radiogenomics, and Next-Generation Molecular Imaging to Augment Diagnosis of Hepatocellular Carcinoma12
Tumor-Infiltrating Lymphocyctes in Triple-Negative Breast Cancer12
Immunotherapy Use in Patients With Lung Cancer and Comorbidities11
Development of Next-Generation Poly(ADP-Ribose) Polymerase 1–Selective Inhibitors10
Incorporating Value-Based Care Into Oncology9
Radiotherapy for Non-Hodgkin Lymphomas9
Role of Microenvironment in Non-Hodgkin Lymphoma9
Obesity and Energy Balance Considerations in Triple-Negative Breast Cancer9
Central Nervous System Lymphoma9
DNA Damage Repair Inhibitors—Combination Therapies8
Mechanistic Effects of Estrogens on Breast Cancer8
Neoantigen-Specific T Cells in Adoptive Cell Therapy8
Interventional Pharmacoeconomics8
c-Met Signaling as a Therapeutic Target in Head and Neck Cancer8
Marginal Zone Lymphomas7
PARP Inhibitors in Triple-Negative Breast Cancer Including Those With BRCA Mutations7
Neurotoxicity Biology and Management7
Stereotactic Body Radiotherapy in Oligomestatic/Oligoprogressive Sarcoma7
Targeted Treatment of Triple-Negative Breast Cancer7
Monoclonal Antibodies in Acute Myeloid Leukemia—Are We There Yet?7
Oligometastatic Disease and Local Therapies7
COVID-19 and Chronic Lymphocytic Leukemia6
Clinical Targeting of Altered Metabolism in High-Grade Glioma6
Targeting Metabolic Pathways in Kidney Cancer6
Minimal Residual Disease in Multiple Myeloma6
Mining the Microenvironment for Therapeutic Targets in Chronic Lymphocytic Leukemia6
Lessons for Oncology From the COVID-19 Pandemic6
Patterns of Enrollment in Cancer Treatment Trials During the COVID-19 Pandemic at National Cancer Institute–Designated Cancer Centers6
Overview of Lung Cancer Immunotherapy6
Local Ablative Therapies for Oligometastatic and Oligoprogressive Non–Small Cell Lung Cancer6
DNA Damage Response in Glioblastoma6
Prognostic and Predictive Factors in Metastatic Renal Cell Carcinoma6
The Role of Radiolabeled Monoclonal Antibodies in Cancer Imaging and ADC Treatment6
Measurable Residual Disease Assessment as a Surrogate Marker in New Drug Development in Acute Myeloid Leukemia6
Prognostic and Predictive Biomarkers in Oligometastatic Disease6
What Are the Prospects for Treating TP53 Mutated Myelodysplastic Syndromes and Acute Myeloid Leukemia?5
Examining the Impact of Tislelizumab Added to Chemotherapy on Health-Related Quality-of-Life Outcomes in Previously Untreated Patients With Nonsquamous Non–Small Cell Lung Cancer5
Surgical Considerations for Tumor Tissue Procurement to Obtain Tumor-Infiltrating Lymphocytes for Adoptive Cell Therapy5
Moving Immunotherapy Into Early-Stage Lung Cancer5
Poly(ADP-Ribose) Polymerase Inhibitor Inhibition in Ovarian Cancer5
Autoimmune Cytopenia in CLL5
Toward the Next Generation of High-Grade Glioma Clinical Trials in the Era of Precision Medicine5
Circulating Plasma Epstein-Barr Virus DNA Load During the Follow-up Periods Predicts Recurrence and Metastasis in Nasopharyngeal Carcinoma5
Advances in Treatment of Follicular Lymphoma5
Current State of Cell Therapies for Breast Cancer5
Is There a Role for Cellular Therapy in Chronic Lymphocytic Leukemia?5
Antibody-Drug Conjugates in Breast Cancer: What Is Beyond HER2?5
The Evolving Molecular Landscape of High-Grade Gliomas5
Therapeutic Targeting of FGFR Signaling in Head and Neck Cancer5
The von Hippel-Lindau Tumor Suppressor Gene5
The Critical Role of the Oncology Nurse as a Partner in the Management of Patients With Advanced Kidney Cancer5
What Is the Standard First-Line Treatment for Advanced Non–Small Cell Lung Cancer?4
STING Agonists in Head and Neck Squamous Cell Carcinoma4
The Role of Targeted Therapy in the Management of High-Risk Resected Kidney Cancer4
Circulating Biomarkers in Glioblastoma4
Imaging and Image-Guided Thermal Ablation for Oligometastatic Colorectal Cancer Liver Disease4
Antibody-Drug Conjugates in Breast Cancer: Spotlight on HER24
Immune Related Adverse Events4
Immune and Cell Therapy in Non-Hodgkin Lymphoma4
Current State of Cell Therapies for Genitourinary Malignancies4
The Evolution of Research and Therapy With Hypomethylating Agents in Acute Myeloid Leukemia and Myelodysplastic Syndrome: New Directions for Old Drugs4
The Clinical Challenges, Trials, and Errors of Combatting Poly(ADP-Ribose) Polymerase Inhibitors Resistance4
Off-the-Shelf Chimeric Antigen Receptor T Cells4
Predictive Biomarkers for Immune Checkpoint Inhibitors in Advanced Non–Small Cell Lung Cancer4
Lessons From the Impact of the COVID-19 Pandemic at the National Cancer Institute4
Hormone Replacement Therapy After Breast Cancer4
Menopausal Hormone Therapy and Breast Cancer4
“Triple-Negative Breast Cancer Central Nervous System Metastases From the Laboratory to the Clinic”4
Chimeric Antigen Receptor T Cells for Multiple Myeloma4
Advanced Imaging and Computational Techniques for the Diagnostic and Prognostic Assessment of Malignant Gliomas3
The Biology of Chronic Lymphocytic Leukemia3
Price, Cost, and Value of Cancer Medicines3
The Challenges and Future of Immunotherapy for Gliomas3
Introduction3
HER2 and HER3 as Therapeutic Targets in Head and Neck Cancer3
The Menopause Management Vacuum3
Time to Treat Financial Toxicity for Patients3
Fecal Microbiota Transplantation as a Cancer Therapeutic3
Epigenetic Dysregulation in Advanced Kidney Cancer3
Combining Isocitrate Dehydrogenase Inhibitors With Existing Regimens in Acute Myeloid Leukemia3
Microbiome and Diet in Colon Cancer Development and Treatment3
Chimeric Antigen Receptor T-Cell Therapy3
Integrating New Therapies for Chronic Lymphocytic Leukemia3
The Gut Microbiome and Pancreatic Cancer Development and Treatment3
Incorporation of FLT3 Inhibitors Into the Treatment Regimens for FLT3 Mutated Acute Myeloid Leukemia3
Precision Radiotherapy for Gliomas3
Using Adoptive Cellular Therapy for Localized Protein Secretion3
Molecular Diagnostics of Non-Hodgkin Lymphoma3
Improving Equity in Cancer Care in the Face of a Public Health Emergency3
Targeting Epidermal Growth Factor Receptor in Head and Neck Cancer3
Chimeric Antigen Receptor Design Today and Tomorrow3
Optimal Management of Chronic Lymphocytic Leukemia and Economic Constraints2
Advances in Classification and Treatment of Non-Hodgkin Lymphoma2
Aurora Kinases as Therapeutic Targets in Head and Neck Cancer2
Emerging Challenges to Cellular Therapy of Cancer2
Telemedicine Across the Cancer Care Continuum2
Neurosurgical Advances for Malignant Gliomas2
Clinical Evidence Generation During a Pandemic2
Evolution of Therapy for Older Patients With Acute Myeloid Leukemia2
Diagnosis, Risk Stratification, and Treatment of Peripheral T-Cell Lymphomas2
PARP Inhibition in Advanced Prostate Cancer2
Toxicities From Antibody-Drug Conjugates2
Tumor-Derived Exosomes and the Role of Liquid Biopsy in Human Papillomavirus Oropharyngeal Squamous Cell Carcinoma2
Chimeric Antigen Receptor T-Cell Therapy for B-Cell Acute Lymphoblastic Leukemia2
Individual Benefits and Risks of Intravaginal Estrogen and Systemic Testosterone in the Management of Women in the Menopause, With a Discussion of Any Associated Risks for Cancer Development2
Preclinical In Vitro and In Vivo Models for Adoptive Cell Therapy of Cancer2
The Microbiome and Liver Cancer2
Estrogen for the Treatment and Prevention of Breast Cancer2
Molecular Classification of Large B-Cell Non-Hodgkin Lymphoma2
Oligometastatic Disease and Interventional Oncology2
Epidemiology and Pathogenesis of Myelodysplastic Syndrome2
Management of Chronic Lymphocytic Leukemia in Less-Resourced Countries2
The Potential for Selective Cyclin-Dependent Kinase 4/6 Inhibition in the Therapy for Head and Neck Squamous Cell Carcinoma2
Cancer Care at the Beginning of the COVID-19 Pandemic2
Update on Pregnancy Following Breast Cancer Diagnosis and Treatment2
Pricing and Paying for Cancer Drugs2
Immunotherapy for Lung Cancer—Improving Outcomes in Patients With Locally Advanced Non–Small Cell Lung Cancer With Immunotherapy2
Local Treatment of Triple-Negative Breast Cancer2
γδ T Cell–Based Adoptive Cell Therapies Against Solid Epithelial Tumors2
Transcription Factors and Cancer2
Therapeutic Response Assessment of High-Grade Gliomas During Early-Phase Drug Development in the Era of Molecular and Immunotherapies2
Evolving Landscape of Antibody Drug Conjugates in Lymphoma2
Targeting HRAS in Head and Neck Cancer2
The Problem of Cancer Drugs Costs2
Poly(ADP-Ribose) Polymerase Inhibition in Small Cell Lung Cancer2
Chimeric Antigen Receptor T Cells for B-Cell Lymphoma2
Monoclonal Antibodies in Myeloma2
0.038707971572876